Gene therapy for cardiomyopathy
CA 2354029 C · Owner: Morishita, Ryuichi · Inventors: Ogihara, Toshio; Morishita, Ryuichi; Taniyama, Yoshiaki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention enables the repair of cardiac function by noninvasive administration of an HGF gene in the form of Sendai virus (HVJ)-liposome into the affected cardiac muscle thereby inducing , angiogenesis of the cardiac muscle layer and repressing fibrosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 5, 2000 and granted January 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 5, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 5, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.